Press release
Biosimilar Market Expected To Reach USD 102.29 Bn by 2032, with a CAGR of 17.02% from 2025 to 2032
Biosimilar Market
Biosimilar Market Overview:
The global biosimilar and follow-on biologics market is witnessing dynamic growth, driven by rising demand for cost-effective biologic treatments and increasing healthcare access across emerging economies. Biosimilars-biological products that are highly similar to already approved biologics-are transforming the pharmaceutical landscape by offering comparable efficacy at lower costs. With patents for many blockbuster biologics expiring, biosimilars are gaining traction in treating chronic conditions such as cancer, autoimmune diseases, and diabetes. Healthcare providers, governments, and insurers are embracing these alternatives as a sustainable solution to balance innovation and affordability.
Download a Free Sample Report Today : https://www.maximizemarketresearch.com/request-sample/83592/
Biosimilar Market Dynamics
Key factors accelerating the market include rising incidences of chronic diseases, growing pressure on healthcare budgets, and regulatory frameworks favoring biosimilar approvals. Leading pharmaceutical companies are forming strategic alliances to bolster R&D and gain competitive advantage. However, challenges such as manufacturing complexities, regulatory variability, and brand loyalty to original biologics remain. Despite these hurdles, advancements in analytical science and biologic manufacturing are boosting confidence among physicians and patients, propelling market adoption across various therapeutic segments.
Biosimilar Market Outlook and Future Trends :
The outlook for the biosimilar market is highly optimistic, with an increasing number of biologic drug patents set to expire in the coming years. Future trends point toward broader therapeutic applications, improved interchangeability standards, and expanding reimbursement support. Additionally, biosimilar penetration is expected to surge in oncology, immunology, and rare diseases, supported by physician education and patient trust. As digital health integrates with biopharmaceutical distribution and pharmacovigilance, biosimilars will become a key pillar in global healthcare cost containment strategies.
Key Recent Developments
Vietnam and Thailand: With government-led initiatives to improve healthcare access, these countries are witnessing rising imports and clinical adoption of biosimilars. Recent collaborations between local hospitals and international manufacturers are expanding the therapeutic reach of biosimilars in public healthcare systems.
Japan: Japan has been proactive in biosimilar integration, supported by its universal healthcare system. Recent joint ventures between domestic pharma firms and global biologic developers are focusing on oncology and nephrology biosimilars to cater to an aging population.
South Korea: South Korea remains a leader in biosimilar innovation, with companies investing heavily in R&D and gaining regulatory approvals in global markets. Strategic mergers have enhanced its position as a global biosimilar exporter, especially in monoclonal antibody therapies.
Singapore: Positioned as a biotech hub, Singapore has recently attracted biosimilar manufacturing investments through its innovation-friendly ecosystem. Collaborations with European biotech firms have accelerated local production capabilities and clinical trial activities.
United States: The U.S. market is evolving rapidly as FDA approvals for biosimilars grow. Key acquisitions by major pharmaceutical players are focused on building robust biosimilar pipelines and ensuring broader commercial access under value-based healthcare models.
Europe: Europe remains the largest and most mature market for biosimilars. Countries like Germany and the UK are implementing competitive tendering processes, while recent cross-border acquisitions aim to enhance biosimilar manufacturing efficiency and regulatory alignment across the region.
To Gain More Insights into the Market Analysis, Browse Summary of the Research Report : https://www.maximizemarketresearch.com/request-sample/83592/
Biosimilar Market Segmentation
by Type
Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Granulocyte-colony stimulating factor
Others
by Technology
Recombinant DNA Technology
Monoclonal Antibodies (MAb) Technology
by Application
Oncology
Inflammatory
Autoimmune diseases
Chronic diseases
Blood disorders
Growth hormone deficiency
Infectious diseases
Other
by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Some of the current players in the Biosimilar Market are:
1. Pfizer Inc.
2. Amgen Inc.
3. Coherus BioSciences
4. Viatris (formerly Mylan)
5. Teva Pharmaceutical Industries
6. Novartis AG (Sandoz)
7. Biocon Biologics
8. Samsung Bioepis
9. Fresenius Kabi
10. Biogen
For additional reports on related topics, visit our website:
♦ Synthetic Biology Market https://www.maximizemarketresearch.com/market-report/synthetic-biology-market-bioinformatics/616/
♦ Global Biopsy Market https://www.maximizemarketresearch.com/market-report/global-biopsy-market/116684/
♦ Global Biological Safety Testing Products & Services Market https://www.maximizemarketresearch.com/market-report/global-biological-safety-testing-products-services-market/117734/
Contact Maximize Market Research:
MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 sales@maximizemarketresearch.com
About Maximize Market Research:
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Market Expected To Reach USD 102.29 Bn by 2032, with a CAGR of 17.02% from 2025 to 2032 here
News-ID: 4013238 • Views: …
More Releases from MAXIMIZE MARKET RESEARCH PVT. LTD
GPS Tracking Device Market Surge Ahead at a CAGR of 13.1% from 2025 to 2032: Sma …
GPS Tracking Device Market size was valued at USD 3.50 Billion in 2024 and the total GPS Tracking Device revenue is expected to grow at a CAGR of 13.1% from 2025 to 2032, reaching nearly USD 9.38 Billion.
GPS Tracking Device Market Overview:
The GPS tracking device market is entering a dynamic growth phase, propelled by mounting demand in logistics, automotive, personal safety, and healthcare industries. Innovations such as IoT integration, telematics,…
Iron and Steel Slag Market to Grow at a CAGR of 1.5% in the Forecast Period of 2 …
The Iron and Steel Slag Market size was valued at USD 25.81 Billion in 2024 and the total Iron and Steel Slag revenue is expected to grow at a CAGR of 1.5% from 2025 to 2032, reaching nearly USD 29.08 Billion.
Iron and Steel Slag Market Overview:
Iron and steel slag, a byproduct of metal smelting, is emerging as a linchpin in modern industrial ecosystems. Far from being waste, this versatile material…
Shooting Ranges Market Expected To Hit USD 2.57 Bn by 2032, with a CAGR of 7.85% …
The Shooting Ranges Market size was valued at USD 1.40 Billion in 2024 and the total Shooting Ranges revenue is expected to grow at a CAGR of 7.85% from 2025 to 2032, reaching nearly USD 2.57 Billion.
Shooting Ranges Market Overview:
Shooting ranges serve as specialized facilities-both indoor and outdoor-where firearms and archery training, recreational shooting, and competitive events take place in controlled, safe environments. These venues support a wide spectrum of…
Fuel Cell UAV Market Taking Flight at Robust Growth Pace: A Clean-Energy Drone R …
The Fuel Cell UAV Market size was valued at USD 1661.38 Million in 2024 and the total Fuel Cell UAV revenue is expected to grow at a CAGR of 13.95% from 2025 to 2032, reaching nearly USD 4722.62 Million.
Fuel Cell UAV Market Overview:
Fuel-cell-powered unmanned aerial vehicles (UAVs) are swiftly redefining the drone landscape with their promise of prolonged flight times and greener operations. Leading aerospace innovators and emerging startups alike…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
